BioXcel Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioXcel Therapeutics, Inc.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
The company is developing a sublingual thin film of dexmedetomidine that could be used to treat agitation in a wide range of indications after planned initial launches in schizophrenia and bipolar disorder.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
This week's company moves include the sudden departure of Celgene's COO, new CEOs at Abeona Therapeutics, Kleo Pharmaceuticals and Corvidia Therapeutics, while board appointments have been made at Neurocentrx, Hemogenyx Pharmaceuticals, Emergex Vaccines and Rezolute Inc.
- Digital Health